These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37649596)

  • 21. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.
    Yang L; Wang F; Wang L; Huang L; Wang J; Zhang B; Zhang Y
    Oncotarget; 2015 Apr; 6(12):10592-603. PubMed ID: 25871392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
    Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
    J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C1q
    Zhang S; Peng W; Wang H; Xiang X; Ye L; Wei X; Wang Z; Xue Q; Chen L; Su Y; Zhou Q
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients.
    Bruschini S; Pallocca M; Sperandio E; D'Ambrosio L; Ascenzi F; De Vitis C; Salvati V; Esposito A; Di Martino S; De Nicola F; Paolini F; Fattore L; Alessandrini G; Facciolo F; Foddai ML; Bassi M; Venuta F; D'Ascanio M; Ricci A; D' Andrilli A; Napoli C; Aurisicchio L; Fanciulli M; Rendina EA; Ciliberto G; Mancini R
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
    Yang J; Lee OJ; Son SM; Woo CG; Jeong Y; Yang Y; Kwon J; Lee KH; Han HS
    Cancer Res Treat; 2018 Jul; 50(3):908-916. PubMed ID: 28934846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
    Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
    Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient.
    Wang Y; Liu Z; Yin H; Hu J; Zhong S; Chen W; Zhao J
    Gene; 2018 Feb; 644():87-92. PubMed ID: 29097164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological significance of microRNA-21 in extracellular vesicles of pleural lavage fluid of lung adenocarcinoma and its functions inducing the mesothelial to mesenchymal transition.
    Watabe S; Kikuchi Y; Morita S; Komura D; Numakura S; Kumagai-Togashi A; Watanabe M; Matsutani N; Kawamura M; Yasuda M; Uozaki H
    Cancer Med; 2020 Apr; 9(8):2879-2890. PubMed ID: 32091667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
    Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
    Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-cell analysis of diverse immune phenotypes in malignant pleural effusion.
    Huang ZY; Shao MM; Zhang JC; Yi FS; Du J; Zhou Q; Wu FY; Li S; Li W; Huang XZ; Zhai K; Shi HZ
    Nat Commun; 2021 Nov; 12(1):6690. PubMed ID: 34795282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
    Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
    Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
    Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
    J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes.
    Yang Q; Zhang H; Wei T; Lin A; Sun Y; Luo P; Zhang J
    Front Immunol; 2021; 12():756722. PubMed ID: 34804043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule.
    Lawal B; Wu ATH; Huang HS
    Front Immunol; 2022; 13():872470. PubMed ID: 35655775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the alternative splicing landscape in lung adenocarcinoma reveals novel prognosis signature associated with B cells.
    Shao MM; Zhai K; Huang ZY; Yi FS; Zheng SC; Liu YL; Qiao X; Chen QY; Wang Z; Shi HZ
    PLoS One; 2023; 18(7):e0279018. PubMed ID: 37432957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sea-urchin-like Au nanocluster with surface-enhanced raman scattering in detecting epidermal growth factor receptor (EGFR) mutation status of malignant pleural effusion.
    Wang L; Guo T; Lu Q; Yan X; Zhong D; Zhang Z; Ni Y; Han Y; Cui D; Li X; Huang L
    ACS Appl Mater Interfaces; 2015 Jan; 7(1):359-69. PubMed ID: 25495142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
    Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
    Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.